- Home
- PRFX vs QNRX Comparison
PRFX vs QNRX Comparison
Compare PRFX & QNRX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- PRFX
- QNRX
- Stock Information
- Founded
- PRFX 2007
- QNRX 2018
- Country
- PRFX Israel
- QNRX United States
- Employees
- PRFX 6
- QNRX N/A
- Industry
- PRFX Biotechnology: Pharmaceutical Preparations
- QNRX Medical/Dental Instruments
- Sector
- PRFX Health Care
- QNRX Health Care
- Exchange
- PRFX Nasdaq
- QNRX Nasdaq
- Market Cap
- PRFX 3.3M
- QNRX 4.3M
- IPO Year
- PRFX 2020
- QNRX N/A
- Fundamental
- Price
- PRFX $1.69
- QNRX $7.20
- Analyst Decision
- PRFX Hold
- QNRX
- Analyst Count
- PRFX 1
- QNRX 0
- Target Price
- PRFX N/A
- QNRX N/A
- AVG Volume (30 Days)
- PRFX 8.5M
- QNRX 4.5K
- Earning Date
- PRFX 08-29-2025
- QNRX 08-07-2025
- Dividend Yield
- PRFX N/A
- QNRX N/A
- EPS Growth
- PRFX N/A
- QNRX N/A
- EPS
- PRFX N/A
- QNRX N/A
- Revenue
- PRFX N/A
- QNRX N/A
- Revenue This Year
- PRFX N/A
- QNRX N/A
- Revenue Next Year
- PRFX N/A
- QNRX N/A
- P/E Ratio
- PRFX N/A
- QNRX N/A
- Revenue Growth
- PRFX N/A
- QNRX N/A
- 52 Week Low
- PRFX $1.25
- QNRX $5.01
- 52 Week High
- PRFX $16.63
- QNRX $54.95
- Technical
- Relative Strength Index (RSI)
- PRFX 54.34
- QNRX 43.44
- Support Level
- PRFX $1.57
- QNRX $7.05
- Resistance Level
- PRFX $3.59
- QNRX $7.30
- Average True Range (ATR)
- PRFX 0.22
- QNRX 0.33
- MACD
- PRFX 0.05
- QNRX 0.05
- Stochastic Oscillator
- PRFX 18.80
- QNRX 41.14
About PRFX PainReform Ltd.
PainReform Ltd is a clinical-stage specialty pharmaceutical company. It is focused on the reformulation of established therapeutics. The company's product PRF-110 is based on the local anesthetic ropivacaine, targeting the post-operative pain relief market. PRF-110 is an oil-based, viscous, clear solution that is deposited directly into the surgical wound bed before closure to provide localized and extended post-operative analgesia.
About QNRX Quoin Pharmaceuticals Ltd.
Quoin Pharmaceuticals Ltd is a clinical stage specialty pharmaceutical company focused on developing and commercializing therapeutic products that treat rare and orphan diseases. Its pipeline comprises three products that collectively have the potential to target a broad number of rare and orphan indications, including Netherton Syndrome, Peeling Skin Syndrome, Palmoplantar Keratoderma, Epidermolysis Bullosa, and others.